AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT05008978 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Test 2
Description: 25g of available carbohydrates from Banana consumed at time -15 min and 25g of available carbohydrates from white bread consumed at time 0 min
Study NCT05008978 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Test 3
Description: 25g of available carbohydrates from White bread consumed at time 0 min and 25g of available carbohydrates from Banana consumed at time 15 min
Study NCT05008978 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Test 4
Description: 25g of available carbohydrates from White bread with 25g of available carbohydrates from Papaya consumed simultaneously at time 0 min
Study NCT05008978 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Test 5
Description: 25g of available carbohydrates from White bread with 25g of available carbohydrates from Apple consumed simultaneously at time 0 min
Study NCT00764517 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: Given IV
Study NCT03431272 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lifitegrast
Description: Eye drop
Study NCT01002820 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ganaxolone
Description: liquid suspension, 50 mg/mL, up to 500 mg/day TID or 1500 mg/day, up to 1 year
Study NCT03516474 — intervention group
Intervention type: DEVICE
Intervention: MIMOSA Diagnostics
Description: The MIMOSA shines different colours of light on your skin. It will not touch your skin, or change how your wound is healing. The MIMOSA is designed to be used alongside the camera that is built into your cell phone, and we will use a cell phone to take a picture of your skin. This picture will tell us how much oxygen is getting to your wound, which can tell us more about how you are healing. The MIMOSA device is an experimental diagnostic tool, and will not influence how your wound is healing.
Study NCT00321087 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: T2000
Description: Dose escalation from 600 to 1000 mg
Study NCT00321087 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: T2000
Description: Placebo followed by T2000 dose escalation from 600 to 1000 mg
Study NCT00321087 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: T2000
Description: Placebo followed by dose escalation from 600 to 1000
Study NCT02661178 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: emodepside (BAY 44-4400)
Study NCT02661178 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Study NCT04834960 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Minimizing Missed Opportunities for Vaccination (MOV)
Description: This bundle of interventions has four components that include: (1) Disseminate (vaccination awareness among healthcare providers and child caregivers); (2) Document (vaccination status); (3) Deploy (vaccines); and (4) Discharge (provide advice/referrals for catch-up and routine vaccinations).
Study NCT03810729 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Smartphone assessment
Description: The smartphone app will be performed on participants randomly assigned to receive this test.
Study NCT03810729 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Modified Allen's Test
Description: The modified Allen's test will be will be performed on participants randomly assigned to receive this test.
Study NCT01369329 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Group 2 ustekinumab 130 mg
Description: Type=exact, unit=mg, number=130, form=solution for injection, route= intravenous use, in a single dose.
Study NCT01369329 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Group 3: ustekinumab approximately 6 mg/kg
Description: Type=range, unit=mg/kg, number=6, form=solution for injection, route= intravenous use, in a single dose.weight-range based ustekinumab doses approximating ustekinumab 6 mg/kg: 260 mg (weight \<= 55 kg), 390 mg (weight > 55 kg and \<= 85 kg), and 520 mg (weight > 85 kg).
Study NCT01369329 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Group 1: Placebo
Description: Form=solution for injection, route=intravenous use, in a single dose.
Study NCT03206788 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Losartan
Description: 25 mg or 50 mg (based on patient's weight) Losartan tablets taken by mouth daily in the morning for week 1 followed by twice daily (one in the morning and one in the evening) on Weeks 2-12.
Study NCT03206788 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Placebo tablets, matching the Losartan intervention, taken by mouth daily in the morning for week 1 followed by twice daily (one in the morning and one in the evening) on Weeks 2-12.
Study NCT02325973 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: PressureWire Certus guidewire
Description: Assessment of IMR index in coronaries through PressureWire Certus guidewire
Study NCT00076453 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Lateral wedge orthotic shoe inserts
Description: Customized lateral wedge orthotic shoe inserts
Study NCT00076453 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Standard orthotic shoe inserts
Description: Neutral orthotic inserts
Study NCT00947791 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ketamine
Description: a single IV infusion of ketamine, IV 0.5 mg/kg
Study NCT00947791 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: midazolam
Description: a single IV infusion of midazolam, 0.045 mg/kg
Study NCT00547001 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Estradiol
Description: 1mg during stabilization \& then a taper to 0.75mg, 0.5mg, 0.25mg, 0.125mg.
Study NCT00547001 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Estradiol
Description: 1mg during stabilization \& then a taper to 0.75mg, 0.5mg, 0.25mg, 0.125mg.
Study NCT00547001 — intervention group
Intervention type: DRUG
Group type: NO_INTERVENTION
Intervention: Estradiol
Description: 1mg during stabilization \& then a taper to 0.75mg, 0.5mg, 0.25mg, 0.125mg.
Study NCT00917644 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Atorvastatin
Description: A single 80 mg dose of marketed 80 mg atorvastatin tablets
Study NCT00917644 — intervention group
Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: Atorvastatin
Description: A single dose of new formulation of 80 mg atorvastatin tablets
Study NCT00645255 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: placebo
Description: placebo one capsule daily
Study NCT00645255 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: sibutramine or placebo
Description: one capsule daily
Study NCT02045030 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: aflibercept + FOLFIRI
Description: Aflibercept (Sanofi and Regeneron) targets the Vascular endothelial growth factor (VEGF) pathway that is a composite decoy receptor based on VEGFR-1 and VEGFR-2 fused to an Fc segment of IgG1. In pre-clinical assessments, aflibercept results in stronger angiogenesis inhibition than bevacizumab, exhibiting at least 100-1000 times higher affinity to the circulating VEGFs. It is postulated that in vivo, the binding of these ligands to aflibercept results in the blockade of tumor angiogenesis along with pruning of existing tumor vascular elements and reduction of VEGF-driven vascular permeability. The expected outcome is reduced growth of primary and metastatic tumors by impeding the density of tumor vasculature and diminishing the abnormal leakiness of tumor vessels that supply matrix components to the cancer.
Study NCT00590928 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: esomeprazole
Description: 40mg once daily
Study NCT00590928 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ranitidine
Description: 50mg every h hours
Study NCT04169971 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Music
Description: Played through headphones during the operation under spinal anaesthesia
Study NCT04716556 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Convalescent plasma
Description: Convalescent plasma will be collected by healthy donors, recovered by COVID19 and, after standard preparation and dosage of neutralizing antibodies, it will be administered to patients with SARS-CoV2 pneumonia
Study NCT04062136 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: stem cell transplantation
Description: Transplantation of umbilical cord mesenchymal stem cells
Study NCT02156245 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: conventional rehabilitation program (including concentric cycle ergometer)
Study NCT02156245 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: cycling included into a conventional rehabilitation program
Study NCT04982003 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: exercise
Description: 10 weekly hour-long classes of drumming to music using large-amplitude, whole-body movements
Study NCT03774823 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: RF and PEMF
Description: RF and PEMF treatment is deployed using either a small or large handpick applied to the skin and moved slow random patterns homogeneously over the area of treatment
Study NCT02150031 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 1% Chlorhexidine
Description: subgingival irrigation
Study NCT02150031 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 1% Chlorhexidine
Description: supragingival irrigation
Study NCT02150031 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Blood extraction
Description: Blood extraction using an intravenous access at baseline, 30 seconds after antiseptic aplication, 30 seconds and 15 minutes after tooth extraction.
Study NCT02150031 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Blood extraction
Description: Blood extraction using an intravenous access at baseline, 30 seconds after antiseptic aplication, 30 seconds and 15 minutes after tooth extraction.
Study NCT02150031 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lidocaine plus adrenaline
Description: local anaesthesia using lidocaine plus adrenaline (1:100,000) no more than 2 cartridges.
Study NCT02150031 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Lidocaine plus adrenaline
Description: local anaesthesia using lidocaine plus adrenaline (1:100,000) no more than 2 cartridges.
Study NCT02150031 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Tooth extraction
Description: dental extraction
Study NCT02150031 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Tooth extraction
Description: dental extraction
Study NCT02034123 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK2879552
Description: Subjects will receive GSK2879552orally with approximately 200 milliliter (mL) of water.
Study NCT03831087 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: TAVR-CMR
Description: CMR protocol for the exact determination of the aortic valve dimensions, valve size and implantation route.
Study NCT03831087 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: TAVR-CT
Description: CT protocol for the exact determination of the aortic valve dimensions, valve size and implantation route.
Study NCT00882414 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FERINJECT® (Ferric carboxymaltose)
Description: FERINJECT® will be administered i.v. into a peripheral vein in the arm. 500 mg FERINJECT® will be diluted to a total volume of 100mL in 0.9% saline for infusion and administered over 15 minutes duration.
Study NCT00882414 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo will be administered i.v. into a peripheral vein in the arm. A total volume of 100mL 0.9% saline will be administered over 15 minutes duration.
Study NCT05347615 — intervention group
Intervention type: PROCEDURE
Intervention: IOL Implantation:EDOF lens
Description: A EDOF lens is implanted in the dominant eye
Study NCT05347615 — intervention group
Intervention type: PROCEDURE
Intervention: IOL Implantation: Monofocal lens
Description: A monofocal lens is implanted in the non dominant eye.
Study NCT01411787 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise
Description: Five woman undergoing neoadjuvant chemotherapy for breast cancer will be randomized to an exercise protocol supervised by an experienced personal trainer. The exercise will be administered three times a week for the 4-6 months of neoadjuvant chemotherapy. The exercise protocol will consist of activities including walking/running up to a mile, calisthenics, and light weightlifting.
Study NCT03773952 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PBF-677
Description: oral small molecule, antagonist of Adenosine A3 receptor (AA3R)
Study NCT03773952 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo oral capsule
Description: Oral capsules
Study NCT04672083 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CPT31
Description: CPT31 (cholesterol-PIE12-2-trimer) is a novel D-peptide HIV entry inhibitor that binds with high affinity to a conserved hydrophobic pocket within the gp41 trimer
Study NCT04672083 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: matching placebo
Study NCT05623566 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Picterus Jaundice Pro
Description: In this study we aim to collect data of newborns with wider range of bilirubin levels to adjust the Picterus JP algorithm and optimize the app performance. This will enable a high qualitative estimation of bilirubin levels in the blood of new-borns for all skin colors.
Study NCT04351412 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Gluma
Description: Gluma is desensitizing agent by (Heraeus Kulzer, Armonk, NY, USA) claimed to treat dentine hypersensitivity in exposed cervical teeth surfaces and was applied to participants using a mini brush applicator tip onto the exposed hypersensitive tooth surface requiring treatment and was allowed to dry for 60 seconds. Then Dentine hypersensitivity (DH) was assessed for tactile, cold, and air blast stimuli immediately after completion of treatment. Subjects were also recalled for re-evaluation at 2 weeks and at 1 month after desensitizing treatment.
Study NCT03495622 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Motivational Interviewing/Text messaging
Description: The intervention is a multi-component one that is tailored to the individual and will target smoking cessation. The CHW, after identifying the individual's stage of behavior change, will provide motivational interviewing and set up an automatic text messaging system with their mobile phones that are structured around a quit date chosen by the participant.~The CHW visits are pre-determined and she monitors the progress of the individual regularly. She may restart the process of determining the stage of behavior change for those who relapse or quit the intervention midway thereby reassigning them to the appropriate phase of the trial
Study NCT03774823 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Ultrasound
Description: Ultrasound is applied to the subject by placing a probe on the treatment area and moving it rapidly and homogeneously over the treatment area
Study NCT04351412 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: fluoride varnish
Description: fluoride varnish is usually applied to patients to prevent caries development but was claimed in some cases to also relief dentine hypersensitivity and was applied as a thin layer to the surface of the tooth using an applicator. The varnish set rapidly, and thereafter moisture contamination was not a concern. Patients were advised to not brush or floss their teeth for a couple of hours and to abstain from hot beverages. DH was assessed for tactile, cold, and air blast stimuli immediately after completion of treatment. Subjects were also recalled for re-evaluation at 2 weeks and at 1 month after desensitizing treatment.
Study NCT01718886 — intervention group
Intervention type: DEVICE
Intervention: Obalon Gastric Balloon
Study NCT03767361 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: packed red blood cells transfusion
Description: packed red blood cells transfusion
Study NCT04351412 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Tetric N-Bond self-etch adhesive
Description: Tetric N-Bond self-etch adhesive is one step dental adhesive and is also claimed to relief dentine hypersensitivity due to blockage of dentinal tubules. It was applied according to the manufacturer's instructions, in a thick layer, for at least 30 seconds, using a light brushing motion. Then, it was dried with a steady stream of air for 3 seconds and light-cured for 10 seconds. DH was assessed for tactile, cold, and air blast stimuli immediately after completion of treatment. Subjects were also recalled for re-evaluation at 2 weeks and at 1 month after desensitizing treatment.
Study NCT01271686 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 0.01% bimatoprost
Description: 0.01% bimatoprost once in the evening for 4 weeks
Study NCT01070420 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: FFR via central venous line
Description: Patients with intermediate coronary artery stenosis were consecutively enrolled. FFR was measured by a standard intravenous (IV) adenosine infusion (140 μg•min-1•kg-1) via Rt central femoral vein.
Study NCT01070420 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: FFR via peripheral venous line
Description: Patients with intermediate coronary artery stenosis were consecutively enrolled. FFR was measured by a standard intravenous (IV) adenosine infusion (140 μg•min-1•kg-1) via continuous peripheral vein.
Study NCT00717730 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Folic Acid
Description: 150µgm/day for 6 months in children older than 11 months and 80µgm in 6 to 11 months.
Study NCT00688363 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: weekly blood glucose profile
Description: once daily self-control of urinary-glucose
Study NCT00688363 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: three-monthly haemoglobin A1c
Description: once daily self-control of urinary-glucose
Study NCT00717730 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Vitamin B12
Description: 1.8µgm/day for 6 months in children older than 11 months and 0.5µgm in 6 to 11 months.
Study NCT00688363 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: no blood-glucose self-control
Description: once daily self-control of urinary-glucose
Study NCT03676686 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Nåva Foot Cream
Description: Nåva Foot Cream is a Medical device (EU class IIa) for the treatment of tinea pedis, heal cracks, calluses and dry feet.
Study NCT04089735 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: APP13007, 0.05%
Description: APP13007 eye drop, 0.05%
Study NCT00717730 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo with no active ingredients
Study NCT00717730 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Folic acid and vitamin B12
Description: Folic acid 150µgm/day for 6 months in children older than 11 months and 80µgm in 6 to 11 months vitamin B12 1.8µgm/day for 6 months in children older than 11 months and 0.5µgm in 6 to 11 months.
Study NCT02698189 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Birabresib Dose 20 mg
Description: Administered as an oral capsule twice a day for 21 consecutive days per cycle.
Study NCT01253603 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: QAW039 capsules once daily for 28 days
Study NCT04089735 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: APP13007, 0.1%
Description: APP13007 eye drop, 0.1%
Study NCT01253603 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo to QAW039 capsules once daily for 28 days
Study NCT01253603 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluticasone propionate inhaler twice daily for 28 days
Study NCT04089735 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: APP13007 Placebo, 0.05%
Description: APP13007 placebo eyedrop, 0.05%
Study NCT04089735 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: APP13007 Placebo, 0.1%
Description: APP13007 placebo eyedrop, 0.1%
Study NCT00488774 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo for golimumab, intravenous infusion administered at Week 0
Study NCT00488774 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Golimumab 1 mg per kg
Description: Golimumab 1 mg per kg intravenous (IV) infusion administered at Week 0
Study NCT02319369 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Milademetan
Description: Milademetan will be administered daily as oral capsules or as a combination of multiple oral capsules containing 5 mg, 20 mg, 80 mg, and/or 200 mg
Study NCT02319369 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZA
Description: AZA will be administered at 75 mg/m\^2 subcutaneously or intravenously
Study NCT00488774 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Golimumab 2 mg per kg
Description: Golimumab 2 mg per kg intravenous (IV) infusion administered at Week 0
Study NCT00488774 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Golimumab 4 mg per kg
Description: Golimumab 4 mg per kg intravenous (IV) infusion at Week 0
Study NCT00764517 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vorinostat
Description: Given PO